Sirolimus, but neither CsA nor tacrolimus, reduces peripheral host CD4+ and CD8+ T-cell numbers in anti-CD40L mAb-treated mice
| Group . | Total no. . | Total donor . | Host CD4 . | Host CD8 . | Host CD19 . |
|---|---|---|---|---|---|
| Non-BMT controls | 111.3 ± 10.9 | 0 ± 0 | 30.5 ± 2.1 | 20.6 ± 2.5 | 58.3 ± 6.3 |
| Hamster IgG | 37.2 ± 5.5 | 0 ± 0 | 10.5 ± 1.9 | 9.3 ± 1.5 | 7.7 ± 1.2 |
| Anti-CD40L | 34.4 ± 6.7 | 10.4 ± 8.66-150 | 6.8 ± 1.76-150 | 3.8 ± 1.16-150 | 5.8 ± 1.1 |
| Anti-CD40L + sirolimus | 28.1 ± 8.0 | 16.1 ± 5.06-150 | 3.0 ± 1.06-150,6-151 | 1.6 ± 0.56-150,6-151 | 3.9 ± 1.86-150 |
| Anti-CD40L + CsA | 58.3 ± 10.56-150,6-151 | 30.5 ± 7.36-150,6-151 | 9.8 ± 2.0 | 4.6 ± 1.06-150 | 6.9 ± 1.9 |
| Anti-CD40L + tacrolimus | 47.9 ± 7.56-151 | 26.3 ± 0.46-150 | 7.8 ± 0.8 | 4.5 ± 0.26-150 | 5.3 ± 0.26-150 |
| Group . | Total no. . | Total donor . | Host CD4 . | Host CD8 . | Host CD19 . |
|---|---|---|---|---|---|
| Non-BMT controls | 111.3 ± 10.9 | 0 ± 0 | 30.5 ± 2.1 | 20.6 ± 2.5 | 58.3 ± 6.3 |
| Hamster IgG | 37.2 ± 5.5 | 0 ± 0 | 10.5 ± 1.9 | 9.3 ± 1.5 | 7.7 ± 1.2 |
| Anti-CD40L | 34.4 ± 6.7 | 10.4 ± 8.66-150 | 6.8 ± 1.76-150 | 3.8 ± 1.16-150 | 5.8 ± 1.1 |
| Anti-CD40L + sirolimus | 28.1 ± 8.0 | 16.1 ± 5.06-150 | 3.0 ± 1.06-150,6-151 | 1.6 ± 0.56-150,6-151 | 3.9 ± 1.86-150 |
| Anti-CD40L + CsA | 58.3 ± 10.56-150,6-151 | 30.5 ± 7.36-150,6-151 | 9.8 ± 2.0 | 4.6 ± 1.06-150 | 6.9 ± 1.9 |
| Anti-CD40L + tacrolimus | 47.9 ± 7.56-151 | 26.3 ± 0.46-150 | 7.8 ± 0.8 | 4.5 ± 0.26-150 | 5.3 ± 0.26-150 |
B6 mice were irradiated with 200 cGy TBI on day − 1 and infused with 40 × 106 BALB/c BM on day 0. Reagents were administered from day − 1 through day + 6. Spleen counts and phenotype were evaluated on day 7 after BMT. Shown are absolute numbers (× 106). n = 4/group.
P ≤ .05 compared with hamster IgG.
P ≤ .05 compared with anti-CD40L mAb as a single agent.